(Q34584223)

3 August 2017

1 reference

title

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders (English)

1 reference

3 August 2017

main subject

biological psychiatry

1 reference

2

Mary Zanarini

1 reference

3 August 2017

1

Sabine C Herpertz

1 reference

3 August 2017

6

Hans-Jürgen Möller

1 reference

3 August 2017

Charles S Schulz

3

1 reference

3 August 2017

Larry Siever

4

1 reference

3 August 2017

Klaus Lieb

5

1 reference

3 August 2017

WFSBP Task Force on Personality Disorders

7

1 reference

3 August 2017

World Federation of Societies of Biological Psychiatry (WFSBP)

8

1 reference

3 August 2017

publication date

1 January 2007

1 reference

World Journal of Biological Psychiatry

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

212-244

1 reference

Avoidant personality disorder: current status and future directions

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Empirical Evidence and Psychotherapy: A Growing Scientific Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Prospective assessment of treatment use by patients with personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine for the treatment of childhood anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

An open clinical trial of cognitive therapy for borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The Personality Disorders Institute/Borderline Personality Disorder Research Foundation randomized control trial for borderline personality disorder: rationale, methods, and patient characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Evaluating three treatments for borderline personality disorder: a multiwave study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

A trial of carbamazepine in borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Obesity and obesity-related illnesses in borderline patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The effect of docosahexaenoic acid on aggression in elderly Thai subjects--a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Validity of the distinction between generalized social phobia and avoidant personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Two-Year Randomized Controlled Trial and Follow-up of Dialectical Behavior Therapy vs Therapy by Experts for Suicidal Behaviors and Borderline Personality Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration international pilot study of personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine in the treatment of borderline and schizotypal personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Antidepressants--do they decrease or increase suicidality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The prevention of recurrent suicidal acts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Schema therapy for patients with borderline personality disorder: a single case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Fluoxetine in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Diagnosis of DSM-III-R personality disorders by two structured interviews: patterns of comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Non-melancholic depression: the contribution of personality, anxiety and life events to subclassification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Omega-3 fatty acids in the treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Quetiapine for the treatment of borderline personality disorder; an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Avoidant personality disorder and social phobia: distinct enough to be separate disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The treatment of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The pathophysiology of schizophrenia disorders: perspectives from the spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of phenelzine and haloperidol in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Predictors of response in generalized social phobia: effect of age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Sustained efficacy of dialectical behaviour therapy for borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Pharmacotherapy of Social Phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

High-risk situations associated with parasuicide and drug use in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Use of selective serotonin reuptake inhibitors in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Discriminating borderline personality disorder from other axis II disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Cognitive features of borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

The Longitudinal Course of Borderline Psychopathology: 6-Year Prospective Follow-Up of the Phenomenology of Borderline Personality Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

Prediction of the 10-year course of borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

DSM-III personality disorder diagnoses in a nonpatient sample. Demographic correlates and comorbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970701685224

10.1080/15622970701685224

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference